Towards a new therapy
for the treatment of
Malignant Mesothelioma

EN · ES · CAT

A Novel BERberine derivative for Malignant MESothelioma

Asbestos exposure is the main risk factor for malignant mesothelioma. This rare and lethal cancer affects the mesothelium: the protective thin layer of tissue that covers many of the internal organs of the body. The tumour has a long latency period taking 20 to 50 years to appear. Because of its aggressiveness and highly resilience, researchers are on the hunt for newer and better treatment strategies. This is indeed the main goal of BERMES: developing a novel molecule with a disruptive mechanism of action that has shown activity in this hard-to-treat tumour.

Imagen Elemento web

Malignant mesothelioma is a rare, aggressive and highly resilient malignancy that affects the arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis.

Read more...

Imagen Elemento web

NAX035 is a novel and selective anticancer agent with a superior profile for oncology conditions. It is a derivative of natural alkaloid Berberine which shows superior activity and pharmacology and safety profile. It shows robust preclinical proof of concept in several in vitro and animal models.

Read more...

10/30/2019 - The Bermes Project will participate in the 7th International mRNA Conference
Dr. Carme Plasencia, CEO of Aromics will present on 11-12 November the progress...

Read more...

10/28/2019 - Working Day on asbestos and its impact on health
On the 15th November 2019, the first scientific working session on asbestos...

Read more...

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the EIC-SMEInst-2018-2020 - SME Instrument phase 2 topic.

European Commission